2022年9期
刊物介紹
Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics: ● Cancer epigenetics ● Cancer stem cell ● Improved in vivo and in vitro cancer models ● Cancer prevention and epidemiology ● Biomarkers for predicting drug response ● Mechanism of drug sensitivity and resistance ● New approaches for cancer detection and diagnosis ● Oncology clinical trials ● Targeted therapy ● Multidisciplinary treatment for cancer Author benefits: ● Easy online submission via Editorial Manager ● Efficient and professional peer-review by expert referees from around the world ● Rapid pre-print online publication ● No charge for publication and Open Access ● International visibility - the journal is available free online
Cancer Biology & Medicine
ORIGINAL ARTICLE
- Exosomal miR-155 from gastric cancer induces cancerassociated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPBβ
- Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy
- Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets
- Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing
- Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis
- Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
- A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer
- Comparison of outcomes between immediate implantbased and autologous reconstruction: 15-year, single-center experience in a propensity score-matched Chinese cohort